Levetiracetam (LEV)

DRUG3 trials

Sponsors

UCB Pharma, UCB Japan Co. Ltd., Sunnybrook Health Sciences Centre

Conditions

EpilepsyEpilepsy, PartialHippocampal HyperactivationPartial Onset SeizuresProdromal Alzheimer Disease

Phase 2

Levetiracetam for Persons at Risk for Alzheimer's Disease

RecruitingNCT07477431

Sunnybrook Health Sciences CentreHippocampal Hyperactivation, Prodromal Alzheimer Disease

Start: 2025-10-23End: 2028-02-01Target: 40Updated: 2026-07-29

Phase 3

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

CompletedNCT00152516

UCB PharmaEpilepsy, Partial

Start: 2004-10-31End: 2008-06-30Updated: 2013-02-12

An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

CompletedNCT01506882

UCB Japan Co. Ltd.Epilepsy, Partial Onset Seizures

Start: 2011-12-31End: 2015-04-30Updated: 2015-12-31

Related Papers

A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures.

2011-08-2936 citations

Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks.

2010-10-0117 citations